NASDAQ:ARTL

Artelo Biosciences Q3 2025 Earnings Results & Report

Artelo Biosciences logo
$1.35 -0.10 (-6.97%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$1.37 +0.02 (+1.26%)
As of 11/20/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Artelo Biosciences missed analyst earnings expectations in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$107.19 versus the -$22.14 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
4:00 PM ET

Artelo Biosciences EPS Results

Actual EPS
-$107.19
Consensus EPS
-$22.14
Beat/Miss
Missed by -$85.05
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 4 quarters

Artelo Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Artelo Biosciences Q3 2025 Earnings FAQ

Artelo Biosciences (NASDAQ:ARTL) reported earnings of -$107.19 per share for Q3 2025, missing the consensus estimate of -$22.14. The report was announced on Wednesday, November 12, 2025.

Artelo Biosciences Earnings Headlines

This Gold Pays Up To 15% (Government Can't Touch It)
Larry Fink foresees $110 trillion in assets being tokenized, bigger than the entire US stock market. $1.6 billion has already moved into tokenized gold vaults. Meanwhile, your physical gold doesn't generate yield. And when governments need money? They confiscate it. In 1933 Roosevelt's Executive Order 6102 seized Americans' gold. Tokenized gold is backed by real bars in institutional vaults, but YOU hold the keys. So the only question that matters right now is whether you'll be holding the assets on the new financial rails when this completes... or whether you'll be the last person stuck on the old ones, watching your wealth get sliced in half because you didn't move when you had the chance. Lending it to traders can pay up to 8-15% annual yield, according to the presenter.tc pixel
See More Artelo Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Artelo Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artelo Biosciences and other key companies, straight to your email.

About Artelo Biosciences

Artelo Biosciences (NASDAQ:ARTL) is a clinical-stage biopharmaceutical company developing treatments that target the endocannabinoid system and related biological pathways. Its research focuses on potential therapies for conditions with significant unmet medical needs, including cancer-related symptoms and pain.

The company’s programs have included ART27.13, a cannabinoid receptor agonist being studied for cancer-related anorexia and cachexia, and ART26.12, a small-molecule inhibitor of fatty acid binding protein 5 under investigation for potential therapeutic applications. Artelo has also developed ART12.11, a cannabidiol-based cocrystal formulation.

Artelo is headquartered in the San Diego area of California. Its work is centered on drug research and development rather than the commercial sale of approved medicines.

View Artelo Biosciences Profile